Matching Placebo (Remternetug) History and Updates

15 events · 2022 – present

Synced daily from openFDA and ClinicalTrials.gov. Last sync: .

0
FDA Approvals
0
Label Revisions
15
Trial Milestones
0
Pivotal Publications
Matching Placebo (Remternetug) — history and updatesFDA approvals, label revisions, recalls, trials, and pivotal publicationsFDA approvalsLabel revisionsRecalls + safetyTrialsPublications202320242025202620272028202920302031203220332034Trial: NCT07056309 2025-06-24 → 2025-12-15 (primary completion)Trial: NCT05552157 2024-11-22 → 2034-03-30 (primary completion)Trial: NCT06647498 2024-11-22 → 2034-03-31 (primary completion)Trial: NCT06653153 2024-10-24 → 2029-04-30 (primary completion)Trial: NCT05463731 2022-08-01 → 2024-04-24 (primary completion)today (2026-05-25)FDA approvalLabel revisionRecall or safetyTrial activityPivotal publication

Source: openFDA, ClinicalTrials.gov via AACT, PubMed · Hipa.ai, 2026-05-25Download chart as PNG

This page tracks every FDA action, clinical trial milestone, and major publication for Matching Placebo (Remternetug) since 2022, drawn from openFDA, ClinicalTrials.gov, and PubMed.

All published updates (1)

2024

Upcoming & expected milestones

Primary completion· ClinicalTrials.gov
Phase 2/Phase 3 primary completion: NCT05552157
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Primary completion· ClinicalTrials.gov
Phase 2/Phase 3 primary completion: NCT06647498
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

Past events

2025
2024
Trial started· ClinicalTrials.gov
Phase 2/Phase 3 trial started: NCT05552157
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Trial started· ClinicalTrials.gov
Phase 2/Phase 3 trial started: NCT06647498
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
2022
Trial started· ClinicalTrials.gov
Phase 3 trial started: NCT05463731
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)

Sources

FDA approvals, label revisions, and recalls come from the public openFDA APIs (Drugs@FDA, Drug Label, Drug Enforcement). Drug-safety communications come from the FDA RSS feed. Trial milestones come from ClinicalTrials.gov via the AACT pg dump. Pivotal-publication events come from PubMed, filtered to high-impact journals linked to a Phase 3 trial in our inventory.